Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q3 EPS of $0.04, $0.07 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $22.5 million versus the consensus estimate of $20.27 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.